MaxCyte (NASDAQ:MXCT) Downgraded to Sell Rating by Wall Street Zen

MaxCyte (NASDAQ:MXCT) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of MaxCyte in a research report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $7.00.

MaxCyte Stock Performance

NASDAQ:MXCT opened at $0.78 on Friday. MaxCyte has a 52 week low of $0.64 and a 52 week high of $3.58. The firm has a market cap of $83.20 million, a price-to-earnings ratio of -1.77 and a beta of 1.22. The firm’s 50-day simple moving average is $1.05 and its 200 day simple moving average is $1.38.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MXCT. Mirabella Financial Services LLP boosted its holdings in shares of MaxCyte by 24.2% during the 3rd quarter. Mirabella Financial Services LLP now owns 8,200,000 shares of the company’s stock valued at $12,956,000 after acquiring an additional 1,600,000 shares in the last quarter. State Street Corp increased its holdings in MaxCyte by 4.0% in the 4th quarter. State Street Corp now owns 2,358,384 shares of the company’s stock worth $3,655,000 after purchasing an additional 91,534 shares in the last quarter. AXA S.A. raised its position in MaxCyte by 123.2% in the second quarter. AXA S.A. now owns 2,202,378 shares of the company’s stock valued at $4,801,000 after purchasing an additional 1,215,481 shares during the last quarter. Kennedy Capital Management LLC bought a new position in MaxCyte in the third quarter valued at about $3,330,000. Finally, Millennium Management LLC boosted its stake in shares of MaxCyte by 1,082.6% during the fourth quarter. Millennium Management LLC now owns 1,292,773 shares of the company’s stock valued at $2,004,000 after purchasing an additional 1,183,461 shares in the last quarter. 68.81% of the stock is currently owned by institutional investors.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.